Stoke Therapeutics (NASDAQ:STOK) Stock: Insider Jonathan Allan Sells 627 Shares

Key Points

• Insider sale: General Counsel Jonathan Allan sold 627 Stoke Therapeutics shares at an average price of $26.33, receiving $16,508.91. The transaction occurred under a pre-arranged Rule 10b5-1 plan, leaving him with 20,598 shares.
• Stock and financial performance: STOK recently traded at $25.62, near the lower end of its 12-month range of $20.32 to $40.22. The company reported a quarterly loss of $0.93 per share, worse than the $0.80 consensus estimate, despite revenue exceeding expectations.
• Analyst outlook: Wall Street’s consensus rating is “Moderate Buy,” with 10 analysts rating the stock Buy and one rating it Sell. The average price target is $44.25, substantially above the recent trading price.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 627 shares of Stoke Therapeutics stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $26.33, for a total value of $16,508.91. Following the completion of the sale, the general counsel directly owned 20,598 shares of the company's stock, valued at approximately $542,345.34. This represents a 2.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jonathan Allan also recently made the following trade(s):

• On Tuesday, August 18th, Jonathan Allan sold 2,861 shares of Stoke Therapeutics stock. The shares were sold at an average price of $32.03, for a total value of $91,637.83.

Stoke Therapeutics Stock Performance

NASDAQ STOK traded down $0.39 during trading hours on Friday, hitting $25.62. 581,420 shares of the company's stock were exchanged, compared to its average volume of 783,759. The business's 50 day moving average is $29.99 and its 200-day moving average is $31.21. Stoke Therapeutics, Inc. has a 12-month low of $20.32 and a 12-month high of $40.22. The firm has a market capitalization of $1.65 billion, a P/E ratio of -7.67 and a beta of 1.26.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The business had revenue of $9.32 million during the quarter, compared to analysts' expectations of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. As a group, equities research analysts anticipate that Stoke Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Institutional Trading of Stoke Therapeutics

A number of institutional investors have recently modified their holdings of the company. Quantbot Technologies LP purchased a new stake in shares of Stoke Therapeutics during the 2nd quarter worth about $34,000. KBC Group NV purchased a new position in Stoke Therapeutics in the first quarter valued at approximately $36,000. Harbour Investments Inc. raised its holdings in Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company's stock valued at $38,000 after buying an additional 898 shares during the period. Western Wealth Management LLC acquired a new position in Stoke Therapeutics during the first quarter valued at approximately $55,000. Finally, EverSource Wealth Advisors LLC grew its stake in Stoke Therapeutics by 195.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company's stock worth $60,000 after buying an additional 1,215 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on STOK. Weiss Ratings reissued a "sell (d)" rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Guggenheim reaffirmed a "buy" rating and set a $60.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Chardan Capital reiterated a "buy" rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday, August 4th. JPMorgan Chase & Co. assumed coverage on shares of Stoke Therapeutics in a research note on Friday, August 21st. They set an "overweight" rating and a $40.00 price objective for the company. Finally, The Goldman Sachs Group reissued a "buy" rating on shares of Stoke Therapeutics in a research note on Thursday, September 10th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $44.25.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc is a biotechnology company developing genetic medicines for severe diseases caused by inadequate protein expression. The company's approach, known as TANGO (Targeted Augmentation of Nuclear Gene Output), uses antisense oligonucleotides to selectively modulate pre-messenger RNA splicing and increase production of functional proteins from disease-associated genes.

Stoke's lead program is zorevunersen (STK-001), an investigational antisense oligonucleotide designed to increase functional NaV1.1 protein expression in people with Dravet syndrome, a severe genetic epilepsy caused primarily by mutations in the SCN1A gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.